- Home
- MURA vs IGC Comparison
MURA vs IGC Comparison
Compare MURA & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- IGC
- Stock Information
- Founded
- MURA 2013
- IGC 2005
- Country
- MURA Ireland
- IGC United States
- Employees
- MURA N/A
- IGC N/A
- Industry
- MURA
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- MURA
- IGC Health Care
- Exchange
- MURA Nasdaq
- IGC Nasdaq
- Market Cap
- MURA 36.0M
- IGC 39.8M
- IPO Year
- MURA N/A
- IGC N/A
- Fundamental
- Price
- MURA $2.09
- IGC $0.40
- Analyst Decision
- MURA Buy
- IGC Strong Buy
- Analyst Count
- MURA 2
- IGC 2
- Target Price
- MURA $6.00
- IGC $4.00
- AVG Volume (30 Days)
- MURA 103.1K
- IGC 902.0K
- Earning Date
- MURA 11-04-2025
- IGC 11-14-2025
- Dividend Yield
- MURA N/A
- IGC N/A
- EPS Growth
- MURA N/A
- IGC N/A
- EPS
- MURA N/A
- IGC N/A
- Revenue
- MURA N/A
- IGC $1,327,000.00
- Revenue This Year
- MURA N/A
- IGC $3.54
- Revenue Next Year
- MURA N/A
- IGC $15.12
- P/E Ratio
- MURA N/A
- IGC N/A
- Revenue Growth
- MURA N/A
- IGC 24.95
- 52 Week Low
- MURA $0.95
- IGC $0.25
- 52 Week High
- MURA $4.74
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- MURA 52.55
- IGC 45.94
- Support Level
- MURA $2.06
- IGC $0.38
- Resistance Level
- MURA $2.10
- IGC $0.43
- Average True Range (ATR)
- MURA 0.01
- IGC 0.02
- MACD
- MURA 0.00
- IGC -0.00
- Stochastic Oscillator
- MURA 66.67
- IGC 43.48
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.